The announcement is based on three retrospective studies examining the real-world treatment of 98,654 hospitalized COVID-19 patients.
In two of the studies, remdesivir reduced patients’ mortality risk by 54 percent and 23 percent.
Remdesivir became the first FDA-approved COVID-19 treatment in October.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
